{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:22:40Z","timestamp":1790259760989,"version":"4.1.0"},"reference-count":30,"publisher":"Korean Cancer Association","issue":"4","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1009364"],"award-info":[{"award-number":["2022R1A2C1009364"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-crt.org"],"crossmark-restriction":true},"short-container-title":["Cancer Res Treat"],"published-print":{"date-parts":[[2023,10,15]]},"abstract":"<jats:p>Purpose Neuregulin 1 (&lt;i&gt;NRG1&lt;\/i&gt;) gene fusion is a potentially actionable oncogenic driver. The oncoprotein binds to ERBB3-ERBB2 heterodimers and activates downstream signaling, supporting a therapeutic approach for inhibiting ERBB3\/ERBB2. However, the frequency and clinicopathological features of solid tumors harboring &lt;i&gt;NRG1&lt;\/i&gt; fusions in Korean patients remain largely unknown.Materials and Methods We reviewed archival data from next-generation sequencing panel tests conducted at a single institution, specifically selecting patients with in-frame fusions that preserved the functional domain. The clinicopathological characteristics of patients harboring &lt;i&gt;NRG1&lt;\/i&gt; fusions were retrospectively reviewed.Results Out of 8,148 patients, &lt;i&gt;NRG1&lt;\/i&gt; fusions were identified in 22 patients (0.27%). The average age of the patients was 59 years (range, 32 to 78 years), and the male-to-female ratio was 1:1.2. The lung was the most frequently observed primary site (n=13), followed by the pancreaticobiliary tract (n=3), gastrointestinal tract (n=2, stomach and rectum each), ovary (n=2), breast (n=1), and soft tissue (n=1). Histologically, all tumors demonstrated adenocarcinoma histology, with the exception of one case of sarcoma. &lt;i&gt;CD74&lt;\/i&gt; (n=8) and &lt;i&gt;SLC3A2&lt;\/i&gt; (n=4) were the most frequently identified fusion partners. Dominant features included the presence of fewer than three co-occurring genetic alterations, a low tumor mutation burden, and low programmed death-ligand 1 expression. Various clinical responses were observed in patients with &lt;i&gt;NRG1&lt;\/i&gt; fusions.Conclusion Despite the rarity of &lt;i&gt;NRG1&lt;\/i&gt; fusions in Korean patients with solid tumors, identification through next-generation sequencing enables the possibility of new targeted therapies.<\/jats:p>","DOI":"10.4143\/crt.2023.682","type":"journal-article","created":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T23:26:48Z","timestamp":1686785208000},"page":"1087-1095","update-policy":"https:\/\/doi.org\/10.4143\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Clinicopathological Characteristics of NRG1 Fusion\u2013Positive Solid Tumors in Korean Patients"],"prefix":"10.4143","volume":"55","author":[{"given":"Yoon Jin","family":"Cha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bio","family":"Joo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choong-kun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo Sup","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2954","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2091"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.127"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(17)31521-1"},{"key":"ref4","first-page":"E2836","volume-title":"EGF and NRG induce phosphorylation of HER3\/ERBB3 by EGFR using distinct oligomeric mechanisms","author":"van Lengerich","year":"2017"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203136"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1201317"},{"key":"ref7","first-page":"6840","volume-title":"A recurrent chromosome breakpoint in breast cancer at the NRG1\/neuregulin 1\/heregulin gene","author":"Huang","year":"2004"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.10218"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-13-0633"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000579"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.03307"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-0160"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0379"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00446"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-1119"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200206000-00010"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13313"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2012.76"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2019.305"},{"key":"ref20","first-page":"4","volume-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","author":"Li","year":"2017"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btv710"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1101\/gr.257246.119"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.14.3.1909"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-015-1852-2"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2013.02.018"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0036"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02097-6"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.04.003"},{"key":"ref30","first-page":"105","volume-title":"Efficacy and safety of zenocutuzumab, a HER2 \u00d7 HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers","author":"Schram","year":"2022"}],"container-title":["Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.682","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-crt.org\/upload\/pdf\/crt-2023-682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T07:15:11Z","timestamp":1697181311000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-crt.org\/journal\/view.php?doi=10.4143\/crt.2023.682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.4143\/crt.2023.682","relation":{},"ISSN":["1598-2998","2005-9256"],"issn-type":[{"value":"1598-2998","type":"print"},{"value":"2005-9256","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,15]]},"assertion":[{"value":"2023-05-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-15","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-15","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}